Purpose. Approximately one-third of the world's population has Toxoplasma gondii infection, and one of the main routes of transmission is organ transplantation. The aim of this study was to evaluate the impact of Toxoplasma infection on liver transplantation patients.
INTRODUCTION
Toxoplasmosis is a global parasitic zoonosis caused by Toxoplasma gondii, which was discovered in 1908 by Nicolle and Manceaux. T. gondii is an obligate intracellular parasite with a complex life cycle, affecting animals and humans [1] . Humans acquire the parasite orally, through the consumption of undercooked meat contaminated with cysts, of vegetables and fruits, or of water contaminated with oocysts [1, 2] . Other routes of transmission are solid organ transplantation [3] and blood transfusions [4, 5] . It is reported that >30 % of the world's population has this infection, with higher incidence rates in tropical countries [6] . However, the impact of globalization and migration on incidence cannot be overlooked [7, 8] . These data should be included in the clinical history of patients, mainly if they are under consideration for an organ transplant. Toxoplasmosis in 80 % of immunocompetent patients is asymptomatic, whereas in immunocompromised patients it can cause fatal encephalitis, myocarditis, pneumonitis, chorioretinitis and generalized lymphadenopathy [9] . Disseminated toxoplasmosis is rare and may be fatal in immunosuppressed patients; this occurs more frequently in patients with AIDS and in donor organ recipients [10] .
The transmission of T. gondii can occur by organ transplantation when the donor is infected and the organ contains cysts. The infection is reactivated in the recipient due to the administration of immunosuppressive drugs before and after transplantation. This immunosuppressive state leads to lower levels of CD4 + T cells [3, 10] , favouring the reactivation of cysts localized in the transplanted organ [11] ; the reactivation of chronic toxoplasmosis can occur if the immunosuppressed recipient had a latent infection before organ transplantation. Regardless, toxoplasmosis can be fatal, or cause ocular and pulmonary damage [12, 13] . A correlation has been observed between the incidence and severity of infectious complications and anti-rejection therapy [14, 15] . Within a short period after transplantation, acute infection caused by T. gondii in recipients is possible, in cases where clinical manifestations of toxoplasmosis were not evident before transplantation and the levels of anti-Toxoplasma antibodies were not detected serologically. In addition, infection can be transmitted when the donor organ is obtained from a deceased donor and testing for Toxoplasma infection is not performed. Therefore, potentially successful liver transplants could be lethal due to a primary toxoplasmosis infection or its reactivation.
In recipients, the duration taken to acquire T. gondii infection varies from 1 week to 9 months after the initiation of immunosuppression, indicating a seroconversion, and/or the presence of tachyzoites in the culture, or positive PCR [16, 17] .
The first report of toxoplasmosis associated with liver transplantation was described by Antony in 1972 [18] . The rate of primary infection or the reactivation of toxoplasmosis in liver transplant recipients is lower than that in transplantation recipients of other organs. In a multicentre study including 11 hospitals, from a total of 15 800 transplant recipients, only 22 cases of toxoplasmosis (0.14 %) were reported. Only 12 of 1979 (0.61 %) heart recipients, six of 7709 (0.08 %) kidney recipients and four of 4872 (0.08 %) liver recipients were included. Reported mortality in recipients with toxoplasmosis was 14 % (three of 22 patients); this value was higher in untreated patients with a late diagnosis [19] .
The administration of trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis has been suggested during the first year after solid organ transplantation; this was recommended to prevent bacterial pneumonia during the first 3 months following transplantation because the crude mortality associated with pneumonia due to Pneumocystis jirovecii was found to exceed 40 % in solid organ transplantation [9] . TMP/SMX prophylaxis reduced the incidence of toxoplasmosis after solid organ transplantation [20] . Disseminated toxoplasmosis after liver transplantation can be fatal [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , because of the complexity of such surgery. The assessment of the risk factors for T. gondii transmission and serological status of the donor and recipient could help to prevent death due to disseminated toxoplasmosis in recipients.
In liver transplantation, it is important to check if the donor and/or recipient has or had surrogate markers of T. gondii infection, or if the recipient has the risk factors involved in transmission of the parasite. This could improve diagnosis and treatment. The inclusion of these checks in the clinical history could eliminate masking of the signs and symptoms of toxoplasmosis, predominantly when recipients have concomitant infections, thereby increasing the risk of death.
Serological diagnostic methods, using the most effective tests to detect antibody titres of IgM or IgG anti-T gondii, such as ELISA, immunosorbent agglutination assay (ISAGA) and immunofluorescence assay (IFA), could be valuable [3] . The IgG anti-T. gondii avidity test distinguishes primary and chronic infections. In cases in which the signs and symptoms are related to Toxoplasma infection, PCR and real-time PCR can prove very useful, since these molecular methods directly identify T. gondii DNA. Tissue culture is used to isolate T. gondii from blood or body fluids [3] . However, molecular diagnostic techniques and tissue culture are not available in most clinical laboratories [30] .
Diagnosis by using computed tomography (CT) and magnetic resonance imaging (MRI) can help to rule out meningitis, massive cerebral oedema, encephalitis and seizures [21] [22] [23] 27] . Radiography is useful when clinical signs such as pneumonitis, multi-organ failure, dyspnoea, fever and acute respiratory failure are present [24, 31, 32] . Examining the eye fundus is key to diagnosing retinochoroiditis and necrotizing retinitis [33] [34] [35] [36] [37] . Liver transplantation is the main therapeutic option in chronic hepatitis B and C patients with severe liver dysfunction, and is a growing indication for patients with unresectable hepatocellular carcinoma. Liver transplantation is the best curative modality for patients with underlying severe liver disease and hepatocellular carcinoma who fulfil the necessary criteria for a transplant. Adequate management of infections could be a determining factor for successful treatment. Therefore, we performed a systematic review to analyse the effect of Toxoplasma infection on liver transplant recipients.
METHODS

Main search strategy
This study was conducted following the general methodology recommended for systematic reviews [38, 39] . The main research question formulated to guide the study search is shown in Fig. 1 .
Seventeen articles met the inclusion criteria (original papers in which Toxoplasma infection was diagnosed through serological, histopathological methods or culture, signs and symptoms, molecular and outcomes). Relevant data were captured on an Excel database. A total of 20 cases were included: one article included two case reports and another included three case reports [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] , as shown in Table 1 .
Database search
Reports published from January 1987 to June 2017 were obtained from a total of 10 databases (PubMed, Lilacs, Medline, Science Direct, Scielo, Ebsco, Springer, Wiley, Google Scholar and OvidMedline) through electronic media.
The keywords used were 'Toxoplasma', 'toxoplasmosis' and 'T. gondii', in combination with 'liver transplant'. The inclusion criteria for data were: full-text papers written in English, case reports and original manuscripts of studies performed on humans.
Two researchers (PRLR and GMAF) carefully reviewed all the selected studies. The inclusion criteria for this analysis were: availability of explicit data on all the independent variables and at least one dependent variable; data collection and criteria eligibility were established to determine the frequency or proportion of each study. The independent variables were: type of article, place, year, recipient age, recipient sex, serological status of the donor and recipient before infection, laboratory diagnostic methods, type and levels of antibodies, treatment doses before and after transplantation, clinical complications, and time of death after transplantation.
The dependent variables were antibody levels (increase or decrease) and seroconversion.
RESULTS
A total of 9496 papers, potentially related to T. gondii infection and liver transplantation, were identified. However, only 22 were selected, and of these, 17 met the inclusion criteria for this systematic review (Table 1) . Data on age and sex were not specified for three recipients (15 %), 11 patients (55 %) were female and six (30 %) were male. The case reports, along with the diagnostic methods used for the detection of T. gondii infection in liver transplantation patients, are detailed in Table 2 .
Serostatus of donors and recipients before and after transplantation
The serological status of 20 cases (both donors and recipients), before and after liver transplantation, were analysed to evaluate whether Toxoplasma infection is a consequence of reactivation or primary infection, and the possible route of transmission. Before transplantation, IgG antibodies were positive in 8/20 (40 %), 4/20 (20 %) and 4/20 (20 %) cases of positive donor and negative recipient (D+/RÀ), negative donor and positive recipient (DÀ/R+), and positive donor and positive recipient (D+/R+), respectively. In 4/20 (20 %) of the cases, both the donor and the recipient (D?/R?) antiToxoplasma antibodies were not specified, and, of these, only one recipient had IgG antibodies that were reported as negative (Table 2) .
Before transplantation, three of four recipients (DÀ/R+) tested positive for IgG anti-Toxoplasma antibodies; after transplantation, these recipients reported an increase in IgG anti-Toxoplasma antibody levels, as well as the presence of tachyzoites. Furthermore, two of the recipients were positive for T. gondii DNA, as evaluated by PCR. The positive IgG levels of the fourth recipient showed no change; nevertheless, the presence of tachyzoites was confirmed through cell culture after liver transplantation (Table 2) .
Prior to transplantation, four cases did not show evidence of anti-Toxoplasma antibodies (D?/R? or D?/RÀ); in contrast, after liver transplantation, three of the recipients tested positive for IgM and/or IgG antibodies, and the presence of bradyzoites was reported in one additional case (Table 2) .
Clinical manifestations after liver transplantation in recipients
The diagnosis of toxoplasmosis was established by the presence of compatible signs and symptoms in 19/20 cases (95 %). Ocular damage was reported in 7/20 (35 %), respiratory complications in 8/20 (40 %) and nervous system damage in 4/20 (20 %) of the recipients (Table 3) . (Table 3) .
Treatment and survival of recipients
Regarding survival, 8/20 (40 %) of the recipients died after presenting clinical symptoms associated with Toxoplasma infection; four of them had cytomegalovirus (CMV) coinfections (Tables 3 and 4) .
DISCUSSION
Primary Toxoplasma infections emerged when organ recipients were seronegative before transplantation, and, after transplantation, displayed at least one positive diagnostic test for T. gondii. In the recipients reported in this study, the presence of IgM or tachyzoites (75 %) and Toxoplasma DNA (50 %) after liver transplantation, in addition to the clinical manifestations related to toxoplasmosis, suggest the presence of primary infection. In all these recipients, clinical manifestations consistent with toxoplasmosis appeared during the first 7 weeks after liver transplantation. Fern andez Sab e et al. [18] reported that of the 22 recipients with toxoplasmosis after solid organ transplantation, 18 (82 %) developed primary infection during the first 6 months after transplantation. In the paediatric population, among seronegative recipients receiving organs from seropositive donors, seroconversion was reported 4-6 weeks after transplantation [26] . Additionally, in seronegative recipients and donors or those with unknown serologies (D?/R? or D?/R-) before transplantation, the presence of IgM without an increase in levels of IgG or bradyzoites, after transplantation, could suggest the presence of primary infection. In such cases, the route of infection could not be defined with precision; however, it is possible that the recipient or donor acquired a primary infection with undetectable levels of antibodies (window phase) in a short period before the transplantation. Another possibility is transmission via blood transfusion during or after liver transplantation.
Reactivation
Of the four recipients who were positive for Toxoplasma infection before transplantation [who received the organ from negative donors (DÀ/R+)], three developed high antiToxoplasma IgG antibody titres after transplantation, while in the other case, the parasite was isolated through cellular culture and then histologically identified. Three of these recipients had clinical complications and died (cases 5, 7 and 8) ( Table 2) .
Mortal disseminated toxoplasmosis has been reported after the reactivation of cysts localized in the organs from the recipient [3] . With regard to seropositive donors and recipients before transplantation (D+/R+), all the recipients displayed the presence of Toxoplasma DNA after liver transplantation, possibly promoted by reactivation; in one case, an increase in IgG and IgM levels was observed, which is characteristic of reactivation. Clinical manifestations such as fever, visual impairment and headache were present 1 month after transplantation (Table 2) .
With regard to treatment, in 10 of the 15 (66 %) recipients who were treated with TMP/SMX or PYR, and two of five (40 %) without these treatments, the Toxoplasma infection resolved and they survived, suggesting that effective prophylaxis or specific treatment is necessary in recipients who are at risk of developing primary infection or reactivation [21, 23, 37] . The current laboratory diagnosis of Toxoplasma infection has both advantages and disadvantages.
Toxoplasma infection can be directly diagnosed through different techniques: the isolation and identification of T. gondii from blood, body fluids or tissues, or through microscopy, bioassays or cellular culture. These methods are performed only in specialized laboratories.
Molecular diagnosis and the detection of
Toxoplasma gondii DNA T. gondii DNA (10-1000 tachyzoites/ml) can be detected by PCR. However, standard commercial kits are unavailable, and there are discrepancies in the reported sensitivity, with a range of 13-97 %, possibly due to the absence of the parasite in the bloodstream at the time of sample collection [30] . Nevertheless, this technique is useful for detection of primary and reactivated infections, mainly in immunocompromised patients.
Indirect method: serology to detect anti-Toxoplasma gondii-specific antibodies in patient serum samples Serological tests have advantages given their use of standard commercial kits, and the fact that most utilize Toxoplasma lysate antigens. Sensitivity and specificity depend on the serological test performed. The presence of a recent infection can be determined by detecting IgM or IgG anti-T. gondii antibodies, or a substantial increase in IgG antibody titre with a low IgG avidity test. The measurement of IgG avidity has been shown to be particularly useful in undetermined situations to differentiate primary and chronic infections, in which there is an absence of IgM and high IgG antibodies of low avidity [40] .
In cases of reactivation, past serological evidence must be obtained along with current laboratory evidence of Toxoplasma infection and clinical manifestations. However, no laboratory test performed alone has proven sufficient in this regard. The diagnostic strategy must be sequential, with different IgG, IgM and IgG antibody avidity assays. Evidence shows that, in some patients, low IgM titres persist over long periods after the acute phase of toxoplasmosis [3] . In addition, false positive serological results may be obtained [41, 42] .
Regarding cytomegalovirus (CMV) co-infections, four of eight patients positive for CMV had fatal outcomes. Case 7 was a patient with a previous Toxoplasma infection (DÀ/ R+), who underwent transplantation twice; after the first transplantation, IgG avidity was confirmed, and Toxoplasma reactivation was suggested. After the second liver transplantation, as shown in the autopsy results, evidence of Toxoplasma cysts based on immunohistochemistry in the lungs, liver and myocardium was obtained. The diagnosis was also confirmed by PCR of bronchoalveolar Finally, the evidence showed that, in recipients with or without CMV co-infections, toxoplasmosis was the main cause of death. CMV can cause immunological impairment, complicating a patient's survival.
Implications of research
The cases reported in this review might not reflect the severity of Toxoplasma infections in liver transplantation patients, because the search for the diagnosis may not have been based upon the aetiological agent; in most cases, due to its clinical likelihood, CMV is implicated.
In conclusion, this review reveals the impact of T. gondii infection on liver transplantation patients. This paper only presents reported cases of Toxoplasma infections in liver transplantation patients; however, the problem may be greater than identified through this review. Therefore, it would be useful to design follow-up studies of Toxoplasma infection in patients with liver transplantation.
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